Downregulation of CDK11 expression effectively inhibits cell proliferation and induces cell death in breast cancer, osteosarcoma, ovarian cancer, and liposarcoma cells as well as xenograft tumors (126–130). Here, CDK11B is linked to osteosarcoma.